Program
zelquistinel
Also written as “Zelquistinel” and “AGN-241751”.
Its studies are mostly in Depressive Disorder, Major, led by Syndeio Biosciences.
Furthest: phase 2, since Jun 22, 20185 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Syndeio Biosciences | 52 open or running | phase 2since Jun 22, 2018 | Jun 22, 2018 | Sep 2027phase 2 · NCT06547489 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 22, 2018First study: phase 2 study in Depressive Disorder, MajorFirst studyNCT03586427 · 251 enrolled · United States
- Oct 30, 2018Phase 2 study in Depressive Disorder, MajorNCT03726658 · 226 enrolled · United States
- Jul 18, 2021Phase 1 study in Depressive Disorder, MajorNCT04981561 · 68 enrolled
- Aug 7, 2024Phase 2 study in Depressive Disorder, MajorNCT06547489 · 164 planned · United States
- Aug 4, 2025Phase 2 study in Depressive Disorder, MajorNCT07115329 · 164 planned · United States
Ahead
- Sep 2027Primary completion: phase 2 study in Depressive Disorder, MajorNCT06547489
- Mar 30, 2028Primary completion: phase 2 study in Depressive Disorder, MajorNCT07115329
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07115329Depressive Disorder, Major · United States | 2 | Recruiting | Mar 30, 2028 | 164 |
| NCT06547489Depressive Disorder, Major · United States | 2 | Recruiting | Sep 2027 | 164 |
| NCT04981561Depressive Disorder, Major | 1 | Completed | Dec 21, 2017 | 68 |
| NCT03726658Depressive Disorder, Major · United States | 2 | Completed | Oct 23, 2019 | 226 |
| NCT03586427Depressive Disorder, Major · United States | 2 | Completed | Jul 22, 2019 | 251 |
How it is read
Names in the registry
- “Zelquistinel”, 2 entries
- “AGN-241751”, 2 entries
- “zelquistinel”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.